About
Commitment to Innovation
Next-Generation CDK Therapies for Cancers Beyond CDK4/6
Restoring durable cell-cycle and transcriptional control in RB-independent, p53-mutant, KRAS-mutant, and treatment-resistant malignancies
Next-Generation CDK Therapies for Resistant Cancers
SPV Therapeutics, Inc. is advancing next-generation, precision cyclin-dependent kinase (CDK) therapies designed to restore durable control of cell-cycle and transcriptional dysregulation in cancers that adapt beyond the therapeutic reach of first-generation CDK4/6 inhibitors.
Built on Nobel Prize–recognized CDK biology, SPV develops balanced, multi-node CDK strategies to address RB-independent, p53-mutated, and treatment-resistant malignancies—disease settings in which conventional CDK4/6 inhibition often shows limited durability.
Headquartered in Research Triangle Park—one of the world’s leading life-science and innovation hubs—SPV operates at the intersection of cancer biology, medicinal chemistry, and translational science, with a singular focus on delivering more durable and inclusive treatment options for patients with hard-to-treat cancers, including triple-negative breast cancer (TNBC) and small-cell lung cancer (SCLC).
Mission
SPV Therapeutics is advancing next-generation cyclin-dependent kinase (CDK)–based therapies designed to restore control of the cell cycle and transcriptional dysregulation that drive cancer progression. While the CDK family represents a clinically validated foundation in oncology, many cancers evade the therapeutic reach of first-generation CDK4/6 inhibitors through intrinsic or acquired resistance.
A growing body of biological evidence underscores the roles of additional CDK family members—such as CDK2 and CDK9—in sustaining proliferation, survival, and oncogenic transcriptional programs in resistant disease states. By integrating deep CDK biology, precision medicinal chemistry, and enantiopure small-molecule design, SPV’s mission and vision are aligned to deliver durable, clinically meaningful cancer control through balanced, multi-node CDK inhibition grounded in cancer-relevant biology, rather than relying on single-node pathway suppression. SPV is developing differentiated therapies for patients with advanced, treatment-resistant, and hard-to-treat cancers.
SPV’s vision is to deliver durable, clinically meaningful cancer control through balanced, multi-node CDK inhibition aligned with cancer-relevant biology, rather than reliance on single-node pathway suppression.
Science
Core Thesis
Cyclin-dependent kinases (CDKs) are central regulators of both cell-cycle progression and transcriptional control. Rather than intensifying single-node CDK4/6 blockade, SPV Therapeutics designs enantiopure, next-generation small-molecule inhibitors that enable **balanced, multi-node CDK modulation—particularly CDK4/6/9—**aligned with cancer-relevant biological dependencies.
This approach is intended to restore more durable control in treatment-resistant and hard-to-treat malignancies by addressing the integrated cell-cycle and transcriptional networks that sustain tumor proliferation and survival.
Scientific Approach
Adaptive Resistance as a Therapeutic Opportunity
Cancer does not fail CDK4/6 therapy—it adapts beyond it, revealing new biological dependencies that motivate next-generation therapeutic strategies. While first-generation CDK4/6 inhibitors have improved outcomes in select cancers, many tumors develop intrinsic or acquired resistance through adaptive rewiring of cell-cycle and transcriptional programs.
SPV Therapeutics was founded on the principle that effective cancer therapy must anticipate and address adaptive tumor biology. Our programs are designed to target disease states that emerge following CDK4/6 inhibition, where conventional approaches may lose durability.
Transformative, Tumor-Agnostic Potential
SPV’s CDK-based programs are designed to address shared cell-cycle and transcriptional dependencies across multiple tumor types, rather than being constrained by tissue of origin or a single biomarker. This tumor-agnostic strategy reflects biological features common to many aggressive and treatment-refractory cancers and is intended to support the development of broader, more durable, and more inclusive cancer control.
Intellectual Property
SPV Therapeutics has established a globally oriented intellectual property foundation supporting its next-generation CDK platform. The company maintains multiple patent families, including global PCT filings (WO2020140052–55), providing coverage across the United States, Europe, Canada, and Australia, with patent life extending through 2040.
These patents encompass novel CDK chemotypes, compositions of matter, and therapeutic uses, positioning SPV374 for long-term exclusivity and durable competitive differentiation. High-quality backup and follow-up molecules further enhance development optionality, subject to completion of standard preclinical and IND-enabling studies.
Pipeline
SPV’s pipeline is intentionally focused on next-generation CDK programs engineered to address resistance, durability, and safety, with translational relevance incorporated from the outset.
1. CDK 4/6/9 Inhibitor Program
SPV Therapeutics’ flagship CDK4/6/9 program is a next-generation approach designed to address adaptive resistance that limits first-generation CDK4/6 inhibitors. By integrating balanced inhibition of CDK4, CDK6, and CDK9, the program targets both cell-cycle control and transcriptional dependencies. The enantiopure, orally bioavailable small-molecule platform is development-ready, supported by scalable chemistry, backup and follow-on molecules, and exploration of emerging modalities. Preclinical activity has been observed across RB-positive and RB-negative models, including aggressive subtypes such as TNBC.
Additional Preclinical Programs:
2. PROTAC CDK Degraders
Targeted CDK degradation strategy with a lead molecule, proof-of-concept data, follow-on libraries, and patent-ready IP.
3. Selective CDK9 Inhibitors
Transcription-focused inhibitors addressing oncogenic dependency and resistance, supported by lead compounds, proprietary libraries, and issued and pending IP.
4. Selective CDK4 Inhibitors
Enantiopure CDK4 inhibitors designed to improve safety and durability, with validated leads, backup compounds, scalable synthesis, and patent-ready IP.
All programs are preclinical and described for scientific and informational purposes only.
Lead Program
SPV374 — CDK4 / CDK6 / CDK9 Inhibitor (Advanced Preclinical)
SPV Therapeutics’ CDK4/6/9 program represents a next-generation approach to cyclin-dependent kinase inhibition designed to address the biological limitations of first-generation CDK4/6 therapies. While selective CDK4/6 inhibitors have demonstrated clinical benefit, their durability is frequently constrained by adaptive resistance mechanisms involving cell-cycle bypass and transcriptional rewiring.
The program integrates balanced inhibition of CDK4, CDK6, and CDK9 to simultaneously regulate G1 cell-cycle progression and transcriptional programs that sustain tumor survival. This multi-node strategy is intended to address resistance pathways that emerge when cell-cycle control alone is insufficient.
Built on enantiopure, precision small-molecule design, the CDK4/6/9 program is orally bioavailable, development-ready, and supported by an established, scalable synthetic process. The program architecture includes backup and follow-on molecules to support continuity and risk mitigation, along with exploration of emerging modalities such as PROTAC-based approaches derived from the same platform.
Preclinical studies indicate activity in both RB-positive and RB-negative cancer models, including aggressive subtypes such as triple-negative breast cancer (TNBC), where first-generation CDK4/6 inhibitors have shown limited activity. Together, these features position the CDK4/6/9 program as a differentiated, next-generation platform designed to deliver more durable cancer control.
Partnering
SPV Therapeutics actively seeks strategic, value-aligned partners to advance its programs toward clinical development. Partnership structures may include:
- Licensing or co-development agreements
- Strategic investments
- IND-enabling collaborations
- Clinical development partnerships
Engagement models are designed to be flexible and milestone-driven, enabling partners to participate at defined stages while preserving alignment with scientific rigor, capital efficiency, and patient-centered outcomes.
Team
Subba R. Katamreddy, Ph.D.
Founder, President & Chief Executive Officer
Dr. Katamreddy is an accomplished medicinal chemist and biotechnology executive with more than three decades of experience spanning academia, global pharmaceutical research and development, and entrepreneurial drug discovery. He is the author and/or co-author of more than 40 peer-reviewed scientific publications and patents.
He earned his Ph.D. in Organic Chemistry from Pondicherry University and held research appointments at the University of Hyderabad, the University of Barcelona, and Emory University. He began his industry career at GlaxoSmithKline, advancing to Principal Scientist and Research Investigator, and later co-founded Vijaya Pharmaceuticals, LLC.
At SPV Therapeutics, Dr. Katamreddy leads the development of a next-generation CDK inhibitor platform, including SPV374, a differentiated enantiopure CDK4/6/9 inhibitor designed to address RB-independent biology, p53-mutated resistance mechanisms, and safety limitations associated with first-generation CDK4/6 therapies.
Administration
Vijaya L. Katamreddy, B.Sc., B.Ed., AAS (Clinical Research & Data Management Professional)
Secretary and Treasurer
Vijaya Katamreddy serves as Secretary of SPV Therapeutics, Inc., a role she has held since the company’s formation in 2017. Her responsibilities include overseeing finance administration, corporate records, and internal documentation that support transparency and accountability. Ms. Katamreddy’s role focuses on ensuring continuity, documentation integrity, and organizational readiness as SPV Therapeutics conducts its research activities and evaluates strategic and partnering opportunities.
Advisors
Scientific and strategic advisory board appointments will be announced in due course.
Contact
SPV Therapeutics, Inc.
104 T.W. Alexander Drive
P.O. Box 14547
Research Triangle Park, NC 27709, USA
Email: ksreddy@spvtherapeutics.com
Website: www.spvtherapeutics.com